

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10848827
	Filing Date		2004-05-19
	First Named Inventor	Phillip A. Patten	
	Art Unit	1647	
	Examiner Name	Seharaseyon, J.	
	Attorney Docket Number	0269us410	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	4414150		1983-11-08	Goeddel, D.		
	2	4885166		1989-12-05	Meyer, F. et al.		
	3	4695623		1987-09-22	Stabinsky, Y.		
	4	4885166		1989-12-05	Meyer, F. et al.		
	5	5985262		1999-11-16	Kinstler, O. et al.		
	6	6610830	B1	2003-08-26	Goeddel D. et al.		
If you wish to add additional U.S. Patent citation information please click the Add button.							Add
U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10848827
Filing Date		2004-05-19
First Named Inventor	Phillip A. Patten	
Art Unit	1647	
Examiner Name	Seharaseyon, J.	
Attorney Docket Number	0269us410	

	1	20040002474	A1	2004-01-01	Heinrichs, V. et al.	
--	---	-------------	----	------------	----------------------	--

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0051873	EP	A2	1982-05-19	Genentech, Inc.		<input type="checkbox"/>
	2	0205404	EP	A2	1986-12-17	Ciba-Geigy AG		<input type="checkbox"/>
	3	0422697	EP	A1	1991-04-17	Amgen, Inc.		<input type="checkbox"/>
	4	0809996	EP	A2	1997-12-03	F. Hoffmann-La Roche AG		<input type="checkbox"/>
	5	0911033	EP	A2	1999-04-28	Amgen, Inc.		<input type="checkbox"/>
	6	20020067105	KR		2002-08-22	SunBio, Inc.		<input checked="" type="checkbox"/>
	7	8302461	WO	A1	1983-07-21	Cetus Corp.		<input type="checkbox"/>
	8	9206707	WO	A1	1992-04-30	Amgen, Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10848827
Filing Date	2004-05-19
First Named Inventor	Phillip A. Patten
Art Unit	1647
Examiner Name	Seharaseyon, J.
Attorney Docket Number	0269us410

9	9524212	WO	A1	1995-09-14	Imperial College		<input type="checkbox"/>
10	9903887	WO	A1	1999-01-28	Bolder Biotechnology, Inc		<input type="checkbox"/>
11	0042175	WO	A1	2000-07-20	Bolder Biotechnology, Inc		<input type="checkbox"/>
12	0125438	WO	A2	2001-04-12	Maxygen, Inc.		<input type="checkbox"/>
13	0187925	WO	A2	2001-11-22	Bolder Biotechnology, Inc		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	ALLEN G., DIAZ M.O. (1996) Nomenclature of the human interferon proteins. J. Interferon Cytokine Res. 1996 Feb; 16(2):181-184.	<input type="checkbox"/>
	2	ALTON, K. et al. (1983) Production, characterization and biological effects of recombinant DNA derived IFN-alpha and IFN-gamma analogs. in The Biology of the Interferon System, 1983, eds. E. DeMaeyer and H. Schellekens, Elsevier Science Publications pp. 119-128.	<input type="checkbox"/>
	3	ALTROCK B.W., et al. (1986) Antiviral and antitumor effects of a human interferon analog, IFN-alpha Con1, assessed in hamsters. J Interferon Res. 1986 Aug; 6(4):405-415.	<input type="checkbox"/>
	4	BLATT L.M., et al. (1996) The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. 1996 Jul; 16(7):489-499.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10848827
Filing Date	2004-05-19
First Named Inventor	Phillip A. Patten
Art Unit	1647
Examiner Name	Seharaseyon, J.
Attorney Docket Number	0269us410

5	CHANG C.C., et al. (1999) Evolution of a cytokine using DNA family shuffling. Nat Biotechnol. 1999 Aug;17(8):793-797.	<input type="checkbox"/>
6	CHEETHAM B.F., et al. (1991) Structure-function studies of human interferons-alpha: enhanced activity on human and murine cells. Antiviral Res. 1991 Jan;15(1):27-39.	<input type="checkbox"/>
7	DIAZ M.O., et al. (1996) Nomenclature of the human interferon genes. J Interferon Cytokine Res. 1996 Feb;16(2):179-180.	<input type="checkbox"/>
8	FISH E.N., et al. (1989) The role of three domains in the biological activity of human interferon-alpha. J Interferon Res. 1989 Feb;9(1):97-114.	<input type="checkbox"/>
9	FOSE S, et al. (2003) Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif. 2003 Jul;30(1):78-87.	<input type="checkbox"/>
10	GANGEMI J.D., et al. (1989) Significant differences in therapeutic responses to a human interferon-alpha B/D hybrid in Rauscher or Friend murine leukemia virus infections. J Interferon Res. 1989 Jun;9(3):275-283.	<input type="checkbox"/>
11	HENCO K., et al. (1985) Structural relationship of human interferon alpha genes and pseudogenes. J Mol Biol. 1985 Sep 20;185(2):227-260.	<input type="checkbox"/>
12	MEISTER A., et al. (1986) Biological activities and receptor binding of two human recombinant interferons and their hybrids. J Gen Virol. 1986 Aug; 67 (Pt 8):1633-1643.	<input type="checkbox"/>
13	OZES O.N., et al. (1992) A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res. 1992 Feb;12(1):55-59.	<input type="checkbox"/>
14	WECK P.K., et al. (1981) Antiviral activities of hybrids of two major human leukocyte interferons. Nucleic Acids Res. 1981 Nov 25; 9(22):6153-6166.	<input type="checkbox"/>
15	International Search Report dated July 2, 2004 for related PCT application PCT/US03/36682 filed Nov. 17, 2003	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10848827
	Filing Date		2004-05-19
	First Named Inventor	Phillip A. Patten	
	Art Unit	1647	
	Examiner Name	Seharaseyon, J.	
	Attorney Docket Number	0269us410	

	16	Written Opinion dated Sept. 15, 2004 for related PCT application PCT/US03/36682 filed Nov. 17, 2003	<input type="checkbox"/>
--	----	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10848827
Filing Date	2004-05-19
First Named Inventor	Phillip A. Patten
Art Unit	1647
Examiner Name	Seharaseyon, J.
Attorney Docket Number	0269us410

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Joanne R. Petithory/	Date (YYYY-MM-DD)	2006-10-27
Name/Print	Joanne R. Petithory	Registration Number	42995

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.